New collaboration combines validated antibodies with advanced chromatin profiling technology to deliver more reliable epigenomic data and accelerate discoveries in gene regulation, biomarker research and drug development.
Abcam, a Danaher company specialising in validated antibodies and assay solutions, has announced a strategic partnership with EpiCypher to strengthen the quality and reliability of epigenomics research through enhanced ChIC/CUT&RUN workflows.
The collaboration brings together Abcam's expertise in antibody development and validation with EpiCypher's CUTANA™ ChIC/CUT&RUN technology, creating a comprehensive solution designed to help researchers generate high-confidence chromatin profiling data with greater consistency and reproducibility.
Epigenomics researchers often face challenges when analysing transcription factors and chromatin dynamics, particularly where limited sample availability and inconsistent antibody performance can affect data quality. The partnership aims to overcome these obstacles by co-developing rigorously validated reagents specifically optimised for ChIC/CUT&RUN applications, helping scientists achieve more dependable experimental results.
As part of the agreement, EpiCypher has applied its established chromatin profiling validation pipeline to assess antibody performance using genome-wide enrichment metrics and knockout cell line controls. These independently generated datasets are now being incorporated into Abcam's antibody validation programme, providing researchers with additional confidence when selecting reagents for epigenomic studies.
The combined approach is expected to streamline experimental workflows while reducing the risk of unreliable results, supporting applications including transcriptional regulation, chromatin biology, biomarker discovery, disease research and precision medicine.
By combining complementary expertise in antibody validation and chromatin profiling, the partnership will provide the scientific community with improved tools for studying gene regulation and biological function. Ultimately, the collaboration is designed to help academic, biotechnology and pharmaceutical researchers generate more robust epigenomic insights, enabling faster scientific discoveries and supporting the development of future diagnostics and targeted therapies.
